Table 1. Clinical trials exploring anti-fibrotic drugs' role in cHP therapy.

Agent	Registration No.	Study design	Population	Aims	Primary end point	State
Nintedanib	NCT02999178 (INBUILD)	Phase III, randomized, double blind, placebo-controlled	Fibrosing ILDs	Efficacy and safety	Annual rate of FVC decline	Completed, published results
Pirfenidone	NCT02496182	Phase II/III, placebo-controlled, open-label, proof of concept	cHP	Efficacy and safety	FVC over 52 weeks	Completed, published results
Pirfenidone	EudraCT 2014–000861-32 DRKS00009822 (RELIEF)	Phase II, randomized, double blind, placebo-controlled	cHP	Efficacy and safety	Absolute change in % FVC from baseline to week 48	Completed
Pirfenidone	NCT02958917	Phase II, randomized, double blind, placebo-controlled	cHP	Efficacy and Safety	Mean change in % FVC from baseline to week 52	Ongoing

cHP: chronic hypersensitivity pneumonitis; ILDs: interstitial lung diseases; FVC: forced vital capacity.